Cargando…
JS-K, a nitric oxide donor, induces autophagy as a complementary mechanism inhibiting ovarian cancer
BACKGROUND: Ovarian cancer (OC) is the second most frequent gynecological cancer and is associated with a poor prognosis because OC progression is often asymptoma-tic and is detected at a late stage. There remains an urgent need for novel targeted therapies to improve clinical outcomes in ovarian ca...
Autores principales: | Liu, Bin, Huang, Xiaojie, Li, Yifang, Liao, Weiguo, Li, Mingyi, Liu, Yi, He, Rongrong, Feng, Du, Zhu, Runzhi, Kurihara, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604176/ https://www.ncbi.nlm.nih.gov/pubmed/31262254 http://dx.doi.org/10.1186/s12885-019-5619-z |
Ejemplares similares
-
Role of human glutathione transferases in biotransformation of the nitric oxide prodrug JS-K
por: Sjödin, Birgitta, et al.
Publicado: (2021) -
JS-K, a nitric oxide pro-drug, regulates growth and apoptosis through the ubiquitin-proteasome pathway in prostate cancer cells
por: Tan, Guobin, et al.
Publicado: (2017) -
TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells
por: Simeone, Ann-Marie, et al.
Publicado: (2008) -
Nitric oxide released from JS-K induces cell death by mitotic catastrophe as part of necrosis in glioblastoma multiforme
por: Günzle, Jessica, et al.
Publicado: (2016) -
JS-K, a Nitric Oxide Prodrug, Has Enhanced Cytotoxicity in Colon Cancer Cells with Knockdown of Thioredoxin Reductase 1
por: Edes, Kornelia, et al.
Publicado: (2010)